Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Aurora O'Brate"'
Autor:
Kaiwen Wang, PharmD, Robyn Du, BS, Sinchita Roy-Chowdhuri, MD, Ziping T. Li, MD, Lingzhi Hong, MD, Natalie Vokes, MD, Yasir Y. Elamin, MD, Celyne Bueno Hume, MD, Ferdinandos Skoulidis, MD, PhD, Carl M. Gay, MD, PhD, George Blumenschein, MD, Frank V. Fossella, MD, Anne Tsao, MD, Jianjun Zhang, MD, PhD, Niki Karachaliou, MD, Aurora O’Brate, PhD, Claudia-Nanette Gann, MD, Jeff Lewis, MS, Waree Rinsurongkawong, PhD, J. Jack Lee, PhD, MS, DDS, Don Lynn Gibbons, MD, PhD, Ara A. Vaporciyan, MD, John V. Heymach, MD, PhD, Mehmet Altan, MD, Xiuning Le, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 8, Pp 100533- (2023)
Introduction: MET amplification is a known resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing clinical benefi
Externí odkaz:
https://doaj.org/article/abe6440483814bd08d4c9b73ab459684
Autor:
John H. Miller, Paraskevi Giannakakou, Ernest Hamel, Peter T. Northcote, Bronwyn Kivell, Pisana Rawson, Janet Crawford, Ada Gjyrezi, Ariane Chan, Daniel Escuin, Aurora O'Brate, Anja Wilmes, Arun Kanakkanthara
Supplementary Tables 1-4, Figures 1-4 from Peloruside- and Laulimalide-Resistant Human Ovarian Carcinoma Cells Have βI-Tubulin Mutations and Altered Expression of βII- and βIII-Tubulin Isotypes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::105051d1cf8ece903dfe8ef6ac184c5b
https://doi.org/10.1158/1535-7163.22497106.v1
https://doi.org/10.1158/1535-7163.22497106.v1
Autor:
Paraskevi Giannakakou, Fadlo R. Khuri, Tso-Pang Yao, Adel El-Naggar, Michael Nivens, Jason Wong, Ernest Hamel, Aurora O'Brate, Jun Zhou, Adam I. Marcus
Supplementary Table 1 from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::856a3e9dbeac01e0c6008eae13305fee
https://doi.org/10.1158/0008-5472.22365200.v1
https://doi.org/10.1158/0008-5472.22365200.v1
Autor:
Paraskevi Giannakakou, Fadlo R. Khuri, Tso-Pang Yao, Adel El-Naggar, Michael Nivens, Jason Wong, Ernest Hamel, Aurora O'Brate, Jun Zhou, Adam I. Marcus
Supplementary Figure Legends from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e9d99d91b16b930af276920a791f65f
https://doi.org/10.1158/0008-5472.22365203
https://doi.org/10.1158/0008-5472.22365203
Autor:
Paraskevi Giannakakou, Fadlo R. Khuri, Tso-Pang Yao, Adel El-Naggar, Michael Nivens, Jason Wong, Ernest Hamel, Aurora O'Brate, Jun Zhou, Adam I. Marcus
Supplementary Figure 2 from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb177a9842051745e9459db8387eb1d
https://doi.org/10.1158/0008-5472.22365206.v1
https://doi.org/10.1158/0008-5472.22365206.v1
Autor:
Paraskevi Giannakakou, Fadlo R. Khuri, Tso-Pang Yao, Adel El-Naggar, Michael Nivens, Jason Wong, Ernest Hamel, Aurora O'Brate, Jun Zhou, Adam I. Marcus
Farnesyl transferase (FT) inhibitors (FTI) are anticancer agents developed to target oncogenic Ras proteins by inhibiting Ras farnesylation. FTIs potently synergize with paclitaxel and other microtubule-stabilizing drugs; however, the mechanistic bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbea850fc99c62c5f0be2b8c94817a30
https://doi.org/10.1158/0008-5472.c.6494576.v1
https://doi.org/10.1158/0008-5472.c.6494576.v1
Autor:
Paraskevi Giannakakou, Fadlo R. Khuri, Tso-Pang Yao, Adel El-Naggar, Michael Nivens, Jason Wong, Ernest Hamel, Aurora O'Brate, Jun Zhou, Adam I. Marcus
Supplementary Figure 1 from The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::012fe276d297d748ee3acf379a6b2b60
https://doi.org/10.1158/0008-5472.22365209.v1
https://doi.org/10.1158/0008-5472.22365209.v1
Autor:
Mo Yang, Helene Vioix, Emma S. Hook, Anthony J. Hatswell, Rachael L. Batteson, Bruce R. Gaumond, Aurora O’Brate, Sanjay Popat, Paul K. Paik
Publikováno v:
Value in Health.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cab5224bd6edcbbb2c18f34160d6ed17
https://doi.org/10.1016/j.jval.2023.02.007
https://doi.org/10.1016/j.jval.2023.02.007
Autor:
Natasha Leighl, Christine Bestvina, Jyoti Patel, Xiuning Le, Remi Veillon, Ian Anderson, Ingel Demedts, Marina Chiara Garassino, Julien Mazières, Masahiro Morise, Egbert Smit, S Peter Eggleton, Aurora O’Brate, Gordon Otto, Rolf Bruns, Karl Maria Schumacher, Paul Paik
Publikováno v:
Neuro-Oncology Advances. 4:i22-i22
BACKGROUND Brain metastases (BMs) occur in 20–40% of patients with METex14 skipping NSCLC. Tepotinib, a highly selective MET inhibitor, demonstrated an objective response rate (ORR) of 49.1% and median duration of response (mDOR) of 13.8 months, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b544b2caac9557c5bb74828df0eb926
https://doi.org/10.1093/noajnl/vdac078.085
https://doi.org/10.1093/noajnl/vdac078.085
Autor:
Ingel K. Demedts, Julien Mazieres, Aurora O'Brate, Ian Churchill Anderson, Jyoti D. Patel, Masahiro Morise, S. Peter Eggleton, M.C. Garassino, Egbert F. Smit, G. Otto, Remi Veillon, Paul K. Paik, Rolf Bruns, Christine M. Bestvina, Karl Maria Schumacher, Xiuning Le
Publikováno v:
Neuro-oncology Advances
Background Brain metastases (BMs) are reported in 20–40% patients with METex14 skipping NSCLC. Tepotinib, a highly selective MET inhibitor, has demonstrated an objective response rate (ORR) of 45% and median duration of response (mDOR) of 11.1 mont
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecd5717f37cbbf848fa6752ceafadfaf
https://doi.org/10.1093/noajnl/vdab071.021
https://doi.org/10.1093/noajnl/vdab071.021